FLT3 and acute myeloid leukemia: As clinical management options evolve, studies focused on class associations with MRD status19, response to emerging therapeutics3 such as FLT3 or IDH37,38 as well as combination regimens (e.g azacytidine and venetoclax)4 are warranted to make definitive determinations for AML patient care.